{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:04:58Z","timestamp":1790744698089,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Reckitt Benckiser Health Limited"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.clinthera.2019.04.040","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T09:08:54Z","timestamp":1560330534000},"page":"1486-1498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative Bioavailability Study of a New Orodispersible Formulation of Ibuprofen Versus Two Existing Oral Tablet Formulations in Healthy Male and Female Volunteers"],"prefix":"10.1016","volume":"41","author":[{"given":"Dalma","family":"Sug\u00e1r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Francombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hanid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.04.040_bib1","series-title":"APM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine","author":"Schug","year":"2015"},{"key":"10.1016\/j.clinthera.2019.04.040_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/ACO.0b013e32834a4f74","article-title":"The progression from acute to chronic pain","volume":"24","author":"Lavand\u2019homme","year":"2011","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.clinthera.2019.04.040_bib3","series-title":"Summary of Product Characteristics for Nurofen 200 Mg Tablets Reckitt Benckiser Healthcare Ltd","year":"2015"},{"key":"10.1016\/j.clinthera.2019.04.040_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/bdd.2510110605","article-title":"The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans","volume":"11","author":"Evans","year":"1990","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.clinthera.2019.04.040_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003088-199834020-00002","article-title":"Clinical pharmacokinetics of ibuprofen. The first 30 years","volume":"34","author":"Davies","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2019.04.040_bib6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2125.1991.tb05500.x","article-title":"Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+) ibuprofen","volume":"31","author":"Evans","year":"1991","journal-title":"Br J Clin Pharmacol"},{"issue":"12 Suppl","key":"10.1016\/j.clinthera.2019.04.040_bib7","first-page":"7S","article-title":"Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen","volume":"36","author":"Evans","year":"1996","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2019.04.040_bib8","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/BF03342662","article-title":"Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen","volume":"20","author":"Evans","year":"2001","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2019.04.040_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40268-014-0070-8","article-title":"Ibuprofen sodium is absorbed faster than standard ibuprofen tablets: results of two open-label, randomized, crossover pharmacokinetic studies","volume":"14","author":"Legg","year":"2014","journal-title":"Drugs R D"},{"issue":"3","key":"10.1016\/j.clinthera.2019.04.040_bib10","article-title":"Single dose oral ibuprofen for acute postoperative pain in adults","volume":"8","author":"Derry","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2019.04.040_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/0976-9668.71663","article-title":"Orodispersible tablets: a new trend in drug delivery","volume":"1","author":"Dey","year":"2010","journal-title":"J\u00a0Nat Sci Biol Med"},{"key":"10.1016\/j.clinthera.2019.04.040_bib12","series-title":"Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Subjects","year":"1964"},{"key":"10.1016\/j.clinthera.2019.04.040_bib13","series-title":"Guideline for Good Clinical Practice E6 (R1)","year":"1996"},{"key":"10.1016\/j.clinthera.2019.04.040_bib14","series-title":"Reckitt Benckiser 400 Mg Tablets","year":"2011"},{"key":"10.1016\/j.clinthera.2019.04.040_bib15","series-title":"CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/Corr ** Guideline on the Investigation of Bioequivalence","year":"2010"},{"key":"10.1016\/j.clinthera.2019.04.040_bib16","series-title":"Bandolier's Little Book of Pain","author":"Moore","year":"2003"},{"key":"10.1016\/j.clinthera.2019.04.040_bib17","series-title":"General Practice Notebook","author":"Gpnotebookcouk","year":"2018"},{"key":"10.1016\/j.clinthera.2019.04.040_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10787-009-0016-x","article-title":"Ibuprofen: pharmacology, efficacy and safety","volume":"17","author":"Rainsford","year":"2009","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.clinthera.2019.04.040_bib19","series-title":"Sector Insight: Analgesics","author":"Campaignlive.co.uk","year":"2018"},{"key":"10.1016\/j.clinthera.2019.04.040_bib20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2125.1999.00902.x","article-title":"Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery","volume":"47","author":"Jamali","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.04.040_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5414\/CPP46055","article-title":"Rapidly dissolving formulations for quick absorption during pain episodes: ibuprofen","volume":"46","author":"Jamali","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.04.040_bib22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0032-5910(01)00415-6","article-title":"Preparation, evaluation and optimization of rapidly disintegrating tablets","volume":"122","author":"Sunada","year":"2002","journal-title":"Powder Technol"},{"key":"10.1016\/j.clinthera.2019.04.040_bib23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2147\/PPA.S29549","article-title":"Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions","volume":"7","author":"Hugtenburg","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clinthera.2019.04.040_bib24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5001\/omj.2010.49","article-title":"An overview of clinical pharmacology of ibuprofen","volume":"25","author":"Bushra","year":"2010","journal-title":"Oman Med J"},{"key":"10.1016\/j.clinthera.2019.04.040_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pain.2013.08.013","article-title":"Faster, higher, stronger? Evidence for formulation and efficacy for ibuprofen in acute pain","volume":"155","author":"Moore","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2019.04.040_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ejp.536","article-title":"Validating speed of onset as a key component of good analgesic response in acute pain","volume":"19","author":"Moore","year":"2014","journal-title":"Eur J Pain"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819302437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819302437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:14Z","timestamp":1758963074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819302437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0149291819302437"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.04.040","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Bioavailability Study of a New Orodispersible Formulation of Ibuprofen Versus Two Existing Oral Tablet Formulations in Healthy Male and Female Volunteers","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.04.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}